CN116261454A - 转录激活蛋白的咪唑并哌嗪抑制剂 - Google Patents

转录激活蛋白的咪唑并哌嗪抑制剂 Download PDF

Info

Publication number
CN116261454A
CN116261454A CN202180068106.3A CN202180068106A CN116261454A CN 116261454 A CN116261454 A CN 116261454A CN 202180068106 A CN202180068106 A CN 202180068106A CN 116261454 A CN116261454 A CN 116261454A
Authority
CN
China
Prior art keywords
cancer
disease
compound
group
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180068106.3A
Other languages
English (en)
Chinese (zh)
Inventor
K·乐
M·索思
P·琼斯
J·克罗斯
T·麦卡福斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CN116261454A publication Critical patent/CN116261454A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202180068106.3A 2020-10-02 2021-09-30 转录激活蛋白的咪唑并哌嗪抑制剂 Pending CN116261454A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063086728P 2020-10-02 2020-10-02
US63/086,728 2020-10-02
PCT/US2021/052898 WO2022072648A1 (en) 2020-10-02 2021-09-30 Imidazopiperazine inhibitors of transcription activating proteins

Publications (1)

Publication Number Publication Date
CN116261454A true CN116261454A (zh) 2023-06-13

Family

ID=80950902

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180068106.3A Pending CN116261454A (zh) 2020-10-02 2021-09-30 转录激活蛋白的咪唑并哌嗪抑制剂

Country Status (11)

Country Link
US (1) US12559497B2 (https=)
EP (1) EP4221709B1 (https=)
JP (1) JP2023544173A (https=)
KR (1) KR20230080441A (https=)
CN (1) CN116261454A (https=)
AU (1) AU2021355480B2 (https=)
CA (1) CA3193745A1 (https=)
DK (1) DK4221709T3 (https=)
IL (1) IL301707A (https=)
MX (1) MX2023003785A (https=)
WO (1) WO2022072648A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4221708A4 (en) 2020-10-02 2024-11-06 Board of Regents, The University of Texas System IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION-ACTIVATING PROTEINS
CA3193745A1 (en) 2020-10-02 2022-04-07 Kang Le Imidazopiperazine inhibitors of transcription activating proteins
AU2024331409A1 (en) * 2023-08-30 2026-03-12 Oncopia Therapeutics, Inc. D/B/A Sk Life Science Labs Compounds and compositions as cbp/p300 degraders and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100093740A1 (en) * 2006-12-22 2010-04-15 Hamed Aissaoui 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
CN105473574A (zh) * 2013-05-17 2016-04-06 森特克森治疗公司 新的生长抑制素受体亚型4(sstr4)激动剂
WO2016086200A1 (en) * 2014-11-27 2016-06-02 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
CN106456628A (zh) * 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
US20190298729A1 (en) * 2018-03-29 2019-10-03 Board Of Regents, The University Of Texas System Imidazopiperazine inhibitors of transcription activating proteins
US20190308978A1 (en) * 2018-04-06 2019-10-10 Board Of Regents, The University Of Texas System Imidazopiperazinone inhibitors of transcription activating proteins

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1537114T3 (da) 2002-08-07 2006-11-13 Novartis Ag Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
MX2008015008A (es) 2006-05-26 2008-12-05 Novartis Ag INHIBIDORES DE SINTASA DE ALDOSTERONA Y/O DE 11ß-HIDROXILASA.
US7943617B2 (en) 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
US8859538B2 (en) 2007-06-21 2014-10-14 Cara Therapeutics, Inc. Uses of substituted imidazoheterocycles
CN101686989B (zh) * 2007-06-21 2016-10-19 卡拉治疗学股份有限公司 取代的咪唑并杂环
CN101417999A (zh) 2007-10-25 2009-04-29 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
CN101468988A (zh) 2007-12-26 2009-07-01 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
CN102076694A (zh) 2008-06-25 2011-05-25 埃科特莱茵药品有限公司 5，6，7，8-四氢-咪唑并[1，5-a]吡嗪化合物
WO2011092120A1 (en) 2010-01-29 2011-08-04 Nerviano Medical Sciences S.R.L. 6,7- dihydroimidazo [1,5-a] pyrazin-8 (5h) - one derivatives as protein kinase modulators
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
US9145418B2 (en) 2011-10-07 2015-09-29 Nerviano Medical Sciences S.R.L. Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors
CN103087067A (zh) 2012-08-02 2013-05-08 盛世泰科生物医药技术(苏州)有限公司 作为二肽基酶抑制剂的化合物及其组合物，以及它们的用途
US9695176B2 (en) 2012-10-18 2017-07-04 Bristol-Myers Squibb Company Substituted imidazo[1,5-a]pyrazines as CGRP receptor antagonists
US20160113893A1 (en) 2013-06-12 2016-04-28 Proximagen Limited New therapeutic uses of enzyme inhibitors
JP6820254B2 (ja) 2014-10-10 2021-01-27 ジェネンテック， インコーポレイテッド 治療用化合物およびその使用
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
EP3445750A4 (en) 2016-04-18 2019-11-27 Celgene Quanticel Research, Inc. THERAPEUTIC COMPOUNDS
JP7014736B2 (ja) 2016-05-24 2022-02-01 ジェネンテック， インコーポレイテッド がんの処置のためのピラゾロピリジン誘導体
EP3464270B1 (en) 2016-05-24 2022-02-23 Genentech, Inc. Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
EP4221708A4 (en) 2020-10-02 2024-11-06 Board of Regents, The University of Texas System IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION-ACTIVATING PROTEINS
CA3193745A1 (en) 2020-10-02 2022-04-07 Kang Le Imidazopiperazine inhibitors of transcription activating proteins

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100093740A1 (en) * 2006-12-22 2010-04-15 Hamed Aissaoui 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
CN105473574A (zh) * 2013-05-17 2016-04-06 森特克森治疗公司 新的生长抑制素受体亚型4(sstr4)激动剂
CN106456628A (zh) * 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2016086200A1 (en) * 2014-11-27 2016-06-02 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
US20190298729A1 (en) * 2018-03-29 2019-10-03 Board Of Regents, The University Of Texas System Imidazopiperazine inhibitors of transcription activating proteins
US20190308978A1 (en) * 2018-04-06 2019-10-10 Board Of Regents, The University Of Texas System Imidazopiperazinone inhibitors of transcription activating proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUHO, ALBERT: "CHEB-Binding Protein (CBP) Expression in Diffuse Large B-Cell Lymphoma (DLBCL) With Clinical Correlation", 《 LABORATORY INVESTIGATION》, vol. 95, no. 1, 11 March 2015 (2015-03-11), pages 351 *
吴军: "组蛋白乙酰转移酶p300/CBP抑制剂的研究进展", 《药学进展》, vol. 43, no. 2, 25 February 2019 (2019-02-25), pages 118 - 126 *

Also Published As

Publication number Publication date
JP2023544173A (ja) 2023-10-20
AU2021355480A1 (en) 2023-05-04
EP4221709B1 (en) 2026-01-21
WO2022072648A1 (en) 2022-04-07
AU2021355480B2 (en) 2026-03-05
CA3193745A1 (en) 2022-04-07
US20230312588A1 (en) 2023-10-05
IL301707A (en) 2023-05-01
EP4221709A4 (en) 2024-10-02
KR20230080441A (ko) 2023-06-07
EP4221709A1 (en) 2023-08-09
MX2023003785A (es) 2023-04-26
US12559497B2 (en) 2026-02-24
DK4221709T3 (da) 2026-04-07
AU2021355480A9 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
CN112165944B (zh) 转录激活蛋白的咪唑并哌嗪抑制剂
US12559497B2 (en) Imidazopiperazine inhibitors of transcription activating proteins
EP3316887B1 (en) Gls1 inhibitors for treating disease
WO2019195846A1 (en) Imidazopiperazinone inhibitors of transcription activating proteins
CN114981248A (zh) 用于治疗疾病的受体相互作用蛋白激酶i的抑制剂
US12540139B2 (en) Imidazopiperazine inhibitors of transcription activating proteins
WO2022192527A1 (en) Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases
HK1253238B (en) Gls1 inhibitors for treating disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination